TMEM86B

Across TCGA pan-cancer cohorts, TMEM86B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMEM86B data layer compared with 24 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher TMEM86B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM86B expression acts as an unfavorable survival marker.

SKCM, STAD, and CESC are the cancer types where TMEM86B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	All	0.156	0.761	<.001	25	view →
STAD	OS	Median	II,III,IV	0.183	0.677	.004	24	view →
CESC	OS	Median	III,IV	0.068	0.756	<.001	12	view →
ACC	OS	Median	All	0.188	0.820	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TMEM86B–SKCM (DFS)

Open the SKCM breakdown →